Edition:
India

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

64.91USD
8:03pm IST
Change (% chg)

$-0.11 (-0.17%)
Prev Close
$65.02
Open
$64.99
Day's High
$64.99
Day's Low
$64.81
Volume
20,583
Avg. Vol
849,846
52-wk High
$78.36
52-wk Low
$61.06

Latest Key Developments (Source: Significant Developments)

Prescient Surgical Raises $10 Million In Series B Investment
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Baxter International Inc ::PRESCIENT SURGICAL RAISES $10 MILLION IN SERIES B INVESTMENT.PRESCIENT SURGICAL SAYS FUNDING ROUND WAS LED BY BAXTER VENTURES, VENTURE INVESTMENT ARM OF BAXTER INTERNATIONAL, INC.  Full Article

Baxter Reports Third-Quarter 2018 Results
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Baxter International Inc ::BAXTER REPORTS THIRD-QUARTER 2018 RESULTS AND UPDATES FINANCIAL OUTLOOK FOR FULL-YEAR 2018.Q3 GAAP EARNINGS PER SHARE $1.00 FROM CONTINUING OPERATIONS.Q3 REVENUE $2.8 BILLION VERSUS I/B/E/S VIEW $2.78 BILLION.Q3 EARNINGS PER SHARE VIEW $0.74 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $2.98 TO $3.00 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q4 2018 ADJUSTED EARNINGS PER SHARE $0.71 TO $0.73 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2018 GAAP EARNINGS PER SHARE $2.90 TO $2.94.COMPANY EXPECTS FULL-YEAR 2018 SALES GROWTH OF APPROXIMATELY 5 PERCENT ON A REPORTED BASIS.COMPANY EXPECTS FULL-YEAR 2018 SALES GROWTH OF APPROXIMATELY 3 PERCENT ON AN OPERATIONAL BASIS.FY2018 EARNINGS PER SHARE VIEW $2.98, REVENUE VIEW $11.20 BILLION -- THOMSON REUTERS I/B/E/S.BAXTER INTERNATIONAL - QTRLY WORLDWIDE SALES TOTALED ABOUT $2.8 BILLION, UP 2 PERCENT ON A REPORTED BASIS, 3 PERCENT ON A CONSTANT CURRENCY BASIS."EXPERIENCED A SLOWER-THAN-EXPECTED RETURN TO PRE-HURRICANE MARIA PURCHASING LEVELS ACROSS CERTAIN BUSINESSES".QTRLY ADJUSTED EPS OF $0.80.BAXTER INTERNATIONAL - QTRLY RESULTS INCLUDED SPECIAL ITEMS $108 MILLION, RELATED TO BUSINESS OPTIMIZATION AND INTANGIBLE AMORTIZATION.QTRLY RESULTS INCLUDED $200 MILLION BENEFIT RELATED TO U.S. FOREIGN TAX CREDIT DEFERRED TAX ASSETS.SAW IMPACT FROM DISTRIBUTOR DESTOCKING FOR SELECT PRODUCTS THAT HAS "DEPRESSED" TOP-LINE PERFORMANCE IN 2018.  Full Article

Baxter Receives CE Mark For Prismax
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Baxter International Inc ::BAXTER RECEIVES CE MARK FOR PRISMAX, THE NEXT-GENERATION SYSTEM FOR CONTINUOUS RENAL REPLACEMENT AND ORGAN SUPPORT THERAPIES.BAXTER INTERNATIONAL - NEW THERMAX BLOOD WARMER ALSO RECEIVES CE MARK TO DELIVER EFFECTIVE BLOOD WARMING FOR A VARIETY OF ORGAN SUPPORT THERAPIES.  Full Article

Baxter Announces U.S. FDA Clearance Of New Bone Graft Substitute, Actifuse Flow
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES U.S. FDA CLEARANCE OF NEW BONE GRAFT SUBSTITUTE, ACTIFUSE FLOW.BAXTER INTERNATIONAL INC - EXPECTS ACTIFUSE FLOW TO BE AVAILABLE TO U.S. CUSTOMERS BY YEAR-END.  Full Article

Baxter International Files For Potential Mixed Shelf Offering Size Not Disclosed
Friday, 24 Aug 2018 

Aug 23 (Reuters) - Baxter International Inc ::BAXTER INTERNATIONAL INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED.  Full Article

Syngene International Expands Collaboration With Baxter Healthcare Corp
Monday, 23 Jul 2018 

July 23 (Reuters) - Syngene International Ltd ::SAYS EXPANDED SCOPE OF ITS RESEARCH AND DEVELOPMENT COLLABORATION WITH BAXTER HEALTHCARE CORPORATION.AS PART OF EXPANSION, SYNGENE WILL SET UP ADDITIONAL INFRASTRUCTURE AT DEDICATED BAXTER GLOBAL RESEARCH CENTER (BGRC).AS PART OF EXPANSION, SYNGENE WILL INCREASE THE SIZE OF ITS SCIENTIFIC TEAM WORKING ON BAXTER PROJECTS .DURATION OF THE AGREEMENT HAS ALSO BEEN EXTENDED UNTIL 2024 .  Full Article

Baxter International Says FDA Released Copy Of A Warning Letter Regarding Co's Ahmedabad Facilities
Wednesday, 18 Jul 2018 

July 17 (Reuters) - Baxter International Inc ::BAXTER INTERNATIONAL SAYS ON JULY 17, FDA RELEASED COPY OF WARNING LETTER REGARDING FDA'S JULY 2017 INSPECTION OF CO'S NEWLY ACQUIRED FACILITIES IN AHMEDABAD.BAXTER INTERNATIONAL - COMING OUT OF 2017 INSPECTION, CO DID NOT INCLUDE ANY 2018 REVENUE FOR NEW CLARIS PRODUCT LAUNCHES IN U.S. IN 2018 FINANCIAL GUIDANCE.BAXTER INTERNATIONAL - RECEIPT OF CLARIS WARNING LETTER DOES NOT CAUSE CO TO CHANGE ITS LONG RANGE FINANCIAL GUIDANCE ISSUED IN MAY 2018 AT THIS TIME.BAXTER INTERNATIONAL INC - RECEIPT OF CLARIS WARNING LETTER DOES NOT CAUSE CO TO MAKE CHANGES TO LONG RANGE FINANCIAL GUIDANCE ISSUED IN MAY 2018.BAXTER INTERNATIONAL INC - EVALUATING OTHER POTENTIAL LOCATIONS, INCLUDING CONTRACT MANUFACTURING ORGANIZATIONS.BAXTER INTERNATIONAL INC - EVALUATING OTHER POTENTIAL LOCATIONS TO SUPPORT PRODUCTION OF NEW PRODUCTS FOR DISTRIBUTION IN U.S..BAXTER INTERNATIONAL INC - EXPECTS REGULATORY MEETING WITH FDA TO OCCUR IN 2018, WITH A REINSPECTION OF FORMER CLARIS INJECTABLES FACILITY TO FOLLOW.BAXTER INTERNATIONAL - EVALUATION ALSO TO MITIGATE RISK OF DELAY IN ABILITY TO REMEDIATE CLARIS INJECTABLES FACILITIES TO FDA'S SATISFACTION BEYOND H1 2020.BAXTER INTERNATIONAL - EVALUATING OTHER LOCATIONS THAT COULD ALSO BE USED TO SUPPORT PRODUCTION OF ANY PENDING PRODUCT APPROVALS.  Full Article

Baxter Declares Dividend And Announces Quarterly Dividend Increase
Tuesday, 8 May 2018 

May 8 (Reuters) - Baxter International Inc ::BAXTER DECLARES DIVIDEND AND ANNOUNCES QUARTERLY DIVIDEND INCREASE.BAXTER INTERNATIONAL INC - ANNOUNCED AN APPROXIMATELY 19% INCREASE IN COMPANY'S QUARTERLY DIVIDEND RATE.BAXTER INTERNATIONAL INC - ANNOUNCED AN APPROXIMATELY 19% INCREASE IN COMPANY'S QUARTERLY DIVIDEND RATE.BAXTER INTERNATIONAL INC - 19 PERCENT RATE INCREASE MADE IN CONNECTION WITH DECLARATION OF A QUARTERLY CASH DIVIDEND OF $0.19 PER SHARE OF COMMON STOCK.  Full Article

Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES U.S. FDA APPROVAL OF READY-TO-USE CARDIOVASCULAR MEDICATION BIVALIRUDIN.BAXTER INTERNATIONAL SAYS U.S. FDA APPROVED BIVALIRUDIN IN 0.9 PERCENT SODIUM CHLORIDE INJECTION.BAXTER INTERNATIONAL INC - BIVALIRUDIN IS EXPECTED TO LAUNCH IN UNITED STATES IN EARLY 2018.  Full Article

Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Mallinckrodt Plc :MALLINCKRODT WILL SELL RECOTHROM® AND PREVELEAK® TO BAXTER.MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS.MALLINCKRODT PLC - WILL RETAIN RAPLIXA FOR TOPICAL USE AND IS EVALUATING STRATEGIC OPTIONS FOR THIS PRODUCT.MALLINCKRODT - ‍ SALE IS ANTICIPATED TO DILUTE CO'S ADJUSTED EARNINGS PER SHARE BY $0.10 TO $0.15 IN 2018, WHICH WILL BE OFFSET BY SHARES REPURCHASED DURING Q4 2017​.MALLINCKRODT PLC - COMPANY WILL DISCONTINUE MARKETING OF RAPLIXA UPON CLOSE OF BAXTER TRANSACTION.MALLINCKRODT PLC - PROCEEDS FROM SALE WILL BE USED BY COMPANY TOWARD PAYING DOWN DEBT.MALLINCKRODT PLC - ‍WRITE-OFF FOR RAPLIXA​ WILL BE REPORTED FOR Q4 2017.  Full Article

Smiths and ICU Medical healthcare merger talks collapse

British engineering firm Smiths Group Plc said on Thursday talks with U.S.-based ICU Medical Inc over a possible 7 billion pound-plus ($9.2 billion) merger of their healthcare businesses had fallen through.